Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
Zeronian, M.R., Doulkeridou, S., van Bergen En Henegouwen, P.M.P., Janssen, B.J.C.(2022) BMC Mol Cell Biol 23: 12-12
- PubMed: 35232398 
- DOI: https://doi.org/10.1186/s12860-022-00412-x
- Primary Citation of Related Structures:  
7OM4, 7OM5 - PubMed Abstract: 
The epidermal growth factor receptor (EGFR) is involved in various developmental processes, and alterations of its extracellular segment are associated with several types of cancers, in particular glioblastoma multiforme (GBM). The EGFR extracellular region is therefore a primary target for therapeutic agents, such as monoclonal antibodies and variable domains of heavy chain antibodies (VHH), also called nanobodies. Nanobodies have been previously shown to bind to EGFR, and to inhibit ligand-mediated EGFR activation.
Organizational Affiliation: 
Structural Biochemistry, Bijvoet Center for Biomolecular Research, Department of Chemistry, Faculty of Science, Utrecht University, Utrecht, The Netherlands.